Precision Biosciences Inc Dossier
Qualitative Analysis
Business overview
Precision BioSciences, Inc. (NASDAQ: DTIL) is a clinical-stage gene editing company headquartered in Durham, North Carolina. The company is dedicated to developing in vivo gene editing therapies using its wholly proprietary ARCUS genome editing platform. ARCUS is a highly specific and versatile platform based on a naturally occurring genome editing enzyme, I-CreI, which allows for precise DNA insertions (knock-ins), deletions (knock-outs), and repairs. ARCUS's relatively small size compared to CRISPR-Cas9 simplifies delivery to target tissues using viral and non-viral methods. Precision's primary clinical focus is on advancing its wholly owned programs, including PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Precision BioSciences has strategically pivoted to focus exclusively on in vivo gene editing therapies utilizing its proprietary ARCUS platform, while out-licensing its ex vivo CAR T assets to partners to reduce operating spend and extend cash runway.
Expected impact: Extends cash runway through 2028 and concentrates scientific focus on high-value in vivo programs like PBGENE-HBV and PBGENE-DMD.
Advancing the first-in-human Phase 1/2a ELIMINATE-B clinical trial evaluating PBGENE-HBV, a novel in vivo gene editing therapy designed to eliminate cccDNA and inactivate integrated HBV DNA to achieve a functional cure for chronic Hepatitis B.
Expected impact: Establish clinical proof of concept for ARCUS-based viral DNA elimination and transition the trial into Part 2 expansion.
Initiating the Phase 1/2 FUNCTION-DMD clinical trial for PBGENE-DMD, an in vivo gene editing candidate utilizing a gene excision approach to restore a near-full length functional dystrophin protein in patients with Duchenne muscular dystrophy.
Expected impact: Demonstrate safety, tolerability, and dystrophin protein expression in ambulatory DMD patients.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Grants TG Therapeutics exclusive worldwide rights to develop and commercialize azer-cel (Azercabtagene Zapreleucel) for autoimmune diseases and other non-oncology indications, allowing Precision to monetize its CAR T technology while focusing on in vivo programs.
Terms: Precision received upfront and near-term payments, including a $7.5 million milestone payment in April 2026 (consisting of $5.25 million cash and $2.25 million equity investment). Precision remains eligible for further development, regulatory, and commercial milestones, plus royalties on net sales.
Imugene assumed global rights to azer-cel for cancer indications and took over Precision's cell therapy manufacturing infrastructure and clinical team, significantly reducing Precision's operating expenses.
Terms: Upfront economics valued at $21 million in cash and equity, plus an $8 million milestone payment received in Q4 2025. Precision is eligible for up to $198 million in additional milestones and double-digit royalties on net sales.
Collaboration utilizing Precision's ARCUS platform for a gene insertion approach to treat neonatal-onset ornithine transcarbamylase (OTC) deficiency.
Terms: Precision is eligible for milestone payments and royalties on future product sales as iECURE advances the candidate (ECUR-506).